Lenalidomide maintenance for diffuse large B‐cell lymphoma patients responding to R‐CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study-Reference-Cited by-同舟云学术

Lenalidomide maintenance for diffuse large B‐cell lymphoma patients responding to R‐CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study

Published:2019-11-08 Issue:1 Volume:189 Page:84-96
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Thieblemont Catherine¹^ORCID,Howlett Susannah²,Casasnovas René‐Olivier³,Mounier Nicolas⁴,Perrot Aurore⁵,Morschhauser Franck⁶,Fruchart Christophe⁷,Daguindau Nicolas⁸,Eygen Koen⁹,Obéric Lucie¹⁰,Bouabdallah Reda¹¹,Pica Gian Matteo¹²,Nicolas‐Virezelier Emmanuelle¹³,Abraham Julie¹⁴,Fitoussi Olivier¹⁵,Snauwaert Sylvia¹⁶,Eisenmann Jean‐Claude¹⁷,Lionne‐Huyghe Pauline¹⁸,Bron Dominique¹⁹^ORCID,Tricot Sabine²⁰,Deeren Dries²¹,Gonzalez Hugo²²,Costello Régis²³,Le Du Katell²⁴,Silva Maria Gomes²⁵,Grosicki Sebastian²⁶,Trotman Judith²⁷,Catalano John²⁸,Caballero Dolores²⁹,Greil Richard³⁰,Cohen Amos M.³¹,Gaulard Philippe³²,Roulin Louise³³,Takeshita Kenichi²,Casadebaig Marie‐Laure³⁴,Tilly Hervé³⁵,Coiffier Bertrand³⁶

Affiliation:

1. Hemato‐Oncology APHP Hôpital Saint‐Louis Paris France

2. Celgene Corporation Summit NJ USA

3. Service d'Hématologie Clinique Centre Hospitalier Universitaire de Dijon and INSERM UMR1231 Dijon France

4. Hématologie Centre Hospitalier Universitaire de Nice – Hôpital de l'Archet Nice France

5. Service d'Hématologie Centre Hospitalier Universitaire de Nancy Nancy France

6. Institute of Hematology‐Transfusion Centre Hospitalier Universitaire Régional de Lille Lille France

7. Service d'Hématologie Institut d'Hématologie de Basse‐Normandie Centre Hospitalier Universitaire de Caen Caen France

8. Service d'Hématologie Clinique Centre Hospitalier Annecy Genevois Annecy France

9. Oncologisch Centrum AZ Groeninge Hospital Kortrijk Belgium

10. Hôpital de Purpan Centre Hospitalier Universitaire de Toulouse Toulouse France

11. Department of Hematology Institut Paoli Calmettes Marseille France

12. Centre Hospitalier de Metropole Savoie Chambery France

13. Cancer Research Center of Lyon Lyon France

14. Centre Hospitalier Universitaire Dupuytren Limoges France

15. Hematology/Oncology Polyclinique Bordeaux Nord Aquitaine Bordeaux France

16. AZ Sint‐Jan Brugge‐Oostende Bruges Belgium

17. Centre Hospitalier de Mulhouse Mulhouse France

18. Centre Hospitalier d'Arras Arras France

19. Institut Jules Bordet Brussels Belgium

20. Centre Hospitalier de Valenciennes Valenciennes France

21. AZ Delta Roeselare Belgium

22. Centre Hospitalier René‐Dubos Pontoise France

23. Hôpital de la Conception Marseille France

24. Clinique Victor Hugo Le Mans France

25. Instituto Português de Oncologia de Lisboa Francisco Gentil Lisboa Portugal

26. Medical University of Silesia Katowice Poland

27. Concord Repatriation General Hospital University of Sydney Concord NSW Australia

28. Frankston Hospital and Monash University Frankston Vic. Australia

29. Hospital Universitario de Salamanca Salamanca Spain

30. Paracelsus Medical University Salzburg Salzburg Cancer Research Institute Salzburg Austria

31. Rabin Medical Center Beilinson Hospital Davidoff Cancer Center Tel Aviv University Ramat Aviv Tel Aviv Israel

32. University Hospital Henri Mondor APHP Créteil France

33. Lymphoid Malignancies Unit AP‐HPGroupe Hospitalier Mondor Créteil France

34. Celgene Corporation Boudry Switzerland

35. Department of Hematology Centre Henri Becquerel UNIROUENINSERMU1245 Rouen France

36. Department of Hematology INSERM U1052 Hospices Civils de Lyon Pierre‐Bénite France

Funder

Celgene

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.16300

Reference29 articles.

1. The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology

2. Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

3. Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

4. Missing quality of life data in cancer clinical trials: serious problems and challenges

5. Diffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Transforming CLL management with immunotherapy: Investigating the potential of CAR T-cells and bispecific antibodies;Seminars in Hematology;2024-01

2. EXABS-141-LYM DLBCL in Older Adults;Clinical Lymphoma Myeloma and Leukemia;2023-09

3. Clinical approaches for integrating machine learning for patients with lymphoma: Current strategies and future perspectives;British Journal of Haematology;2023-05-11

4. Lenalidomide maintenance fails to overcome the unfavourable prognosis of low NK‐cell counts in rituximab–chemotherapy responsive elderly DLBCL patients: A LYSA group study;British Journal of Haematology;2023-02-06

5. Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma;Blood;2022-11-24